Table 1.
Drugs of clinical trials for HR neuroblastoma interventetion
| ClinicalTrials ID | Original study | Phase | Status | Referencea |
|---|---|---|---|---|
| NCT00026312 | Isotretinoin With or Without Dinutuximab, Aldesleukin and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | phase III | Completed | Yu AL et al., 2010 [6] |
| NCT01704716 | High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN) | phase III | Recruiting | Dobrenkov K & Cheung NK, 2014 [7] |
| NCT01822652 | 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN | phase I | Active, not recruiting | Heczey A & Louis CU, 2013 [8] |
| NCT02395666 | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | Phase 2 | Active, not recruiting | Wallick CJ et al., 2005 [64] |
| NCT01586260 | Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission | Phase 2 | Active, not recruiting | Wallick CJ et al., 2005 [64] |
| NCT01059071 | Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide | Phase 1 | Completed | Wallick CJ et al., 2005 [64] |
| NCT02097810 | Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1 or ALK Molecular Alterations | phase I | Recruiting | Lee J et al., 2015 [83] |
| NCT01742286 | Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) | phase I | Recruiting | Schulte JH et al., 2013 [69] |
| NCT01871805 | A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer | phase II | Active, not recruiting | McKeage K, 2015 [86] |
| NCT01049841 | Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors | phase I | Active, not recruiting | Rodrik-Outmezguine VS et al., 2011 [104] |
| NCT01767194 | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | Phase 2 | Recruiting | Geoerger B et al., 2012 [105] |
a References are cited in review manuscript